devices, often in vitro diagnostics (IVDs), intended to aid in selecting appropriate therapies for patients. To qualify for the Breakthrough Device Pathway, a CDx must significantly improve the diagnosis of a condition or enhance the safety or effectiveness of a corresponding therapy. A clear definition of “breakthrough” hinges on the potential of the device to address unmet medical needs and facilitate patient outcomes.

Eligibility Criteria

The following eligibility criteria must be met for a device to qualify for the Breakthrough Device Program:

• Proven Potential for Significant Benefits: Demonstrated ability to provide enhanced safety or efficacy over existing alternatives.
• Treatment of Serious Conditions: The device must be intended for conditions that are life-threatening or irreversibly debilitating.
• Clear Evidence Supporting the Device’s Claims: The manufacturer should have preliminary clinical evidence demonstrating safety and effectiveness.

Potential applicants should gather data reflecting early feasibility and preliminary clinical evidence, which will be integral when seeking designation. Notably, the FDA encourages engagement early in the development process, offering guidance that can help clarify regulatory expectations and streamline the pathway.

Step 2: Planning for Submission

Once the decision to pursue the Breakthrough Device Pathway has been established, the next crucial step is planning for submission. This phase involves assembling a detailed development and submission strategy, which outlines the evidence to be gathered and contemplates regulatory challenges ahead.

In this step, some practical actions include:

• Identify Relevant Regulatory Frameworks: Determine whether the device will be subject to Investigational Device Exemption (IDE) or will require an Investigational New Drug application (IND) if it is used alongside a new therapy.
• Outline a Clinical Development Plan: This should detail study designs for clinical trials required to provide substantial evidence of safety and effectiveness. Include a plan for clinical validation that aligns with the evidence expected by the FDA for review.
• Create Documentation Checklists: Document all potential clinical endpoints, secondary measures, and necessary validations that align with the investigational protocols for obtaining clinical evidence.

Aiding in the submission strategy includes collecting data pertaining to qualitative assessments and quantitative results from planned clinical studies, as these will form the backbone of the eventual submission package.

Step 3: Compiling the Dossier and Essential Documentation

The next major step in navigating the FDA Breakthrough Device Pathway is compiling the regulatory dossier. The dossier must reflect robust data supporting the safety and effectiveness of the companion diagnostic device and must adhere to FDA requirements.

The following items should be included in the regulatory dossier:

• Device Description: Offer a complete description of the CDx, including intended use, design characteristics, and operating principles.
• Evidence of Safety and Effectiveness: Include data from any preclinical studies, as well as results from clinical studies conducted under IDEs or concepts supporting the use of INDs if applicable.
• Labeling and Instructions for Use: Draft clear and comprehensive instructions intended for both healthcare professionals and patients, consistent with FDA expectations and guidelines.
• Quality Assurance and Manufacturing Information: Present information demonstrating compliance with Quality Management Systems pertinent to current Good Manufacturing Practices (cGMP).

Document preparation should align with the principles outlined in the International Conference on Harmonisation (ICH) guidelines, ensuring information is presented clearly and comprehensively for reviewers. The use of templates that resonate with FDA expectations can help streamline this process.

Step 4: Navigating the Submission Process

This step involves formally submitting the application along with all compiled documents to the FDA. The Breakthrough Device Application can be submitted through various formats, primarily the 510(k) premarket notification or Premarket Approval (PMA) application, depending on the device classification.

Upon submission, take note of the following:

• Submission Format: Ensure the use of FDA’s electronic submission gateway (eSubmitter) for electronic submissions or follow the guidelines for paper submissions.
• Include All Required Fees: Confirm that the necessary user fee, if applicable, is submitted along with the application to avoid any processing delays.
• Document Communication: Maintain open lines of communication with FDA reviewers. Consider a meeting request after submission to discuss the review process and any anticipated questions or challenges.

As the application is under review, regulatory consultants should prepare for potential requests for additional information (RAIs) from the FDA. Being proactive and well-prepared can significantly enhance the review process’s efficiency.

Step 5: Managing the Review Process

The review of an FDA Breakthrough Device submission can be expedited, but it is crucial to understand that the review process is rigorous. The FDA will assess the safety and effectiveness of the device based on the dossier submitted.

To ensure a smooth review process, stakeholders should:

• Timely Response to RAIs: Prepare a strategy for compiling timely and accurate responses to any questions or RAIs issued by the FDA during the review period.
• Engage in Interactive Dialogue: Utilize meetings with the FDA to clarify data interpretations and discuss scientific requirements. Engagement helps in refining expectations for the evidentiary needs throughout the review.
• Plan for Post-Market Surveillance: Outline risk management and post-market surveillance strategies as part of your regulatory compliance to maintain FDA communication and transparency.

Continuous engagement and clear communication during the review contribute to an enhanced understanding by the FDA of the intended uses and benefits of the companion diagnostic, potentially leading to accelerated approvals.

Step 6: Post-Approval Commitments and Market Launch

Upon receiving approval through the Breakthrough Device pathway, the next phase involves fulfilling any post-approval commitments. Post-market commitments may include clinical studies to validate device performance further or registry activities to monitor long-term safety and effectiveness.

Key actions in this stage should consist of:

• Compliance with Post-Market Requirements: Ensure adherence to any post-approval study commitments as mandated by the FDA, including submitting interim results during the study period.
• Establish Post-Market Surveillance Mechanisms: Implement processes to collect real-world data around the companion diagnostic’s performance, user experience, and any device-related adverse events.
• Regular Updates to Labeling: Maintain ongoing updates to labeling and user instructions based on newly gathered data and findings from post-market studies.

Successful navigation of the post-marketing phase is critical for the sustained market presence of the CDx, ensuring continued compliance with regulatory requirements and fostering trust with healthcare providers and patients.

Step 7: Continuous Improvement and Compliance

Finally, the iterative process of regulatory compliance does not conclude upon approval. Continuous improvement should be a focal point for organizations that have successfully brought a companion diagnostic to market. This involves assessing internal processes and implementation of learnings derived from clinical experiences and market feedback. Regulatory affairs professionals should focus on:

• Regular Internal Audits: Conduct routine audits of regulatory compliance within the organization, ensuring all departments remain aligned with FDA requirements and industry standards.
• Training and Education: Promote continuous education regarding regulatory changes and FDA guidelines among the team to remain at the forefront of compliance obligations.
• Proactive Monitoring of Regulatory Developments: Stay updated with changes in regulations from the FDA and other relevant authorities such as the EMA or ICH related to companion diagnostics.

By following these steps, regulatory professionals will be better equipped to navigate the complexities of the FDA Breakthrough Device Pathway for companion diagnostics in 2023, ensuring thorough preparation, compliance, and ongoing improvement.